Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many claims about muscle injury, liver enzyme monitoring, and interaction-associated increased myopathy risk are broadly supported by the provided label excerpts. Several specific risk-factor and management details (older age, kidney problems, uncontrolled hypothyroidism, dose-higher relationship, and some interaction specifics) are either partially supported, not supported, or framed more generally than the excerpt supports. Some management actions (e.g., switching statins/alternative lipid-lowering strategies) are not directly supported by the provided text.
Category Scores
Accurate Statements
Lipitor (atorvastatin) can cause side effects, especially muscle-related symptoms.
Section 5.1 describes myopathy (muscle aches/weakness) and rhabdomyolysis cases.
Lipitor (atorvastatin) can cause muscle pain, weakness, or cramps.
Section 5.1: myopathy defined as muscle aches or muscle weakness; patients advised to report muscle pain, tenderness, or weakness.
Lipitor (atorvastatin) can cause rare severe muscle injury.
Section 5.1: rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported.
Statins such as Lipitor can raise liver enzymes.
Section 5.2: biochemical abnormalities of liver function; persistent elevations of serum transaminases; liver enzyme changes.
Clinicians may monitor liver tests after starting or changing the dose of Lipitor.
Section 5.2: liver function tests prior to and at 12 weeks following initiation and any elevation of dose, and periodically thereafter.
Risk of muscle injury with Lipitor is higher in older age.
Section 8.5: advanced age (≥65 years) is a predisposing factor for myopathy.
Drug-drug interactions can increase statin levels and raise the chance of side effects.
Section 5.1: concomitant use of higher doses with certain drugs (e.g., strong CYP3A4 inhibitors) increases risk of myopathy/rhabdomyolysis. Section 7: risk of myopathy increased with concurrent administration of certain agents.
Lipitor can interact with other medicines, increasing atorvastatin exposure.
Section 5.1 links certain interacting agents (including cyclosporine and strong CYP3A4 inhibitors) and higher doses to increased risk of myopathy/rhabdomyolysis; Table 1 provides specific prescribing recommendations for interacting agents.
Lipitor interacts with certain antibiotics/antifungals.
Section 5.1 and Section 7: clarithromycin, erythromycin, and azole antifungals; itraconazole noted.
Lipitor interacts with some HIV or hepatitis C treatments.
Section 5.1 and Section 7: HIV protease inhibitors (ritonavir plus saquinavir or lopinavir plus ritonavir). (No hepatitis C agents are mentioned in provided excerpts.)
When interactions raise atorvastatin drug levels, the odds of muscle symptoms and other adverse effects increase.
Section 5.1: concomitant use of higher doses with certain drugs (e.g., strong CYP3A4 inhibitors) increases risk of myopathy/rhabdomyolysis; Section 7 describes increased myopathy risk with concurrent administration of specified agents.
Clinicians warn patients to report new muscle pain, tenderness, weakness, or dark urine promptly if severe muscle injury occurs.
Section 5.1: patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever; rhabdomyolysis described with myoglobinuria (implied dark urine in the claim) and medication should be discontinued if myopathy diagnosed or suspected.
If muscle symptoms occur with Lipitor, clinicians may check creatine kinase.
Section 5.1: myopathy defined as muscle aches/weakness with increases in CPK values >10 times ULN; periodic CPK determinations may be considered in interacting situations.
If muscle symptoms occur with Lipitor, clinicians may review interacting medications.
Section 5.1: clinicians should carefully weigh benefits/risks and carefully monitor for signs/symptoms with specified concomitant drugs; recommendations summarized in Table 1.
If muscle symptoms occur with Lipitor, clinicians may lower the dose.
Section 5.1: LIPITOR therapy should be discontinued if markedly elevated CPK or myopathy diagnosed or suspected; Section 5.2: dose reduction used when transaminase elevations occur (not specific to muscle). The claim specifically says “lower the dose” for muscle symptoms; direct text supports discontinuation/withholding rather than dose-lowering. Therefore this one is treated as partially unsupported.
If muscle symptoms occur with Lipitor, clinicians may switch to a different statin.
No explicit support in provided excerpts.
If muscle symptoms occur with Lipitor, clinicians may use alternative lipid-lowering strategies.
No explicit support in provided excerpts.
Unsupported Statements
Risk of muscle injury with Lipitor is higher in people with kidney problems.
Label excerpt supports renal impairment as a risk factor and says closer monitoring is warranted, but it does not explicitly state 'kidney problems' as a general higher risk population statement in the same phrasing.
Risk of muscle injury with Lipitor is higher in people with uncontrolled hypothyroidism.
Uncontrolled hypothyroidism is not mentioned in the provided label excerpts.
Risk of muscle injury with Lipitor is higher at higher statin doses.
The excerpt supports increased risk with higher doses of atorvastatin when taken with certain drugs (e.g., strong CYP3A4 inhibitors), but it does not support a general statement that muscle injury risk is higher at higher doses independent of concomitant drugs.
Lipitor is a long-term daily medication.
No dosing frequency/duration (daily/long-term) is stated in the provided excerpts.
Long-term use of Lipitor can involve ongoing side-effect monitoring.
The excerpt recommends periodic CPK determinations 'in such situations' and periodic liver function tests after initiation and dose elevation; it does not support a general long-term statement as phrased.
Stopping statins can cause cholesterol levels to rise again.
No statement about cholesterol rebound after stopping statins is included in provided excerpts.
Cholesterol levels rising again after stopping statins can undermine the benefit of Lipitor.
No statement about benefit undermined by discontinuation or cholesterol rebound is included in provided excerpts.
If muscle symptoms occur with Lipitor, clinicians may check liver enzymes.
The provided excerpt addresses liver function tests for initiation/dose changes and monitoring elevated transaminase levels; it does not state checking liver enzymes in response to muscle symptoms.
If muscle symptoms occur with Lipitor, clinicians may lower the dose.
For skeletal muscle, the excerpt states therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected; it does not describe dose lowering for muscle symptoms.
Contradictions
Important Omissions
Boxed warning / contraindications details (Section 4) and hepatic contraindication specifics are not evaluated because the provided excerpts do not include the Contraindications section text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are supported (muscle adverse reactions/rhabdomyolysis, liver enzyme monitoring schedule, interaction-associated increased myopathy risk, and patient reporting of muscle symptoms). However, some claims are unsupported or overly generalized (hypothyroidism, general higher-dose relationship, long-term daily use, rebound cholesterol after stopping, and specific management steps like switching statins/alternative lipid-lowering strategies or checking liver enzymes in response to muscle symptoms).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Some specific risk-factor and management statements are not supported by the provided label excerpts or are generalized beyond the text (e.g., hypothyroidism, general higher-dose risk, dose-lowering for muscle symptoms, switching statins/alternative strategies, liver enzyme checks specifically for muscle symptoms, and discontinuation/rebound cholesterol statements).
Suggested Improvement
Limit claims to the provided label language: emphasize myopathy/rhabdomyolysis and renal impairment as a risk factor (with closer monitoring), specify that increased risk is described particularly with certain interacting drugs and higher atorvastatin doses in those contexts, adhere to the stated liver monitoring schedule, and align muscle-symptom management to discontinuation/withholding and considering interacting medications/possible CPK determinations as described.